FDA Confirms SeaStar Medical Completed QUELIMMUNE Follow-Up Obligations

On November 3, 2026, the U.S. FDA determined that SeaStar Medical’s QUELIMMUNE pediatric registry had satisfied the follow-up obligations tied to its humanitarian device exemption. Hospitals can now use the therapy without the registry-related research infrastructure previously required, potentially widening access for eligible children with acute kidney injury. Registry results showed survival at day 90 of 65.1% among treated patients versus 47.5% in the comparison group, while SeaStar Medical plans to keep collecting voluntary registry data.

The FDA decision removes a procedural barrier to hospital use, which could expand the therapy’s commercial reach. SeaStar Medical’s shares were reported lower at $2.07, indicating a negative market reaction despite the access change.

  • 1The FDA found that SeaStar Medical’s pediatric QUELIMMUNE registry had met the follow-up conditions attached to the device’s humanitarian exemption.
  • 2At day 90, survival was 65.1% for 43 QUELIMMUNE-treated patients and 47.5% for 196 patients in the comparison dataset, with P=0.043.
  • 3SeaStar Medical will continue voluntary registry enrollment at participating medical centers.
  • 4QUELIMMUNE is intended for pediatric patients with sepsis-related acute kidney injury who require renal replacement therapy.
  • 5SeaStar Medical’s shares were reported at $2.07, down 5.09%.

Sources